HALO News and Press, Halozyme Therapeutics Inc. From 02/21/23

Halozyme Therapeutics press release ( NASDAQ: HALO ): Q4 Non-GAAP EPS of $0.48 beats by $0.01 . Revenue of $181.5M (+77.9% Y/Y) misses by $10.55M . Record Fourth Quarter Royalty Revenue Increased 69% YOY to $106.0 million; Record Full Year Royalty Revenue Increased 77%...

HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS PR Newswire Fourth Quarter Revenue Increased 78% YOY to $181 million ; GAAP Diluted Earnings per Share of $0.42 and Non-GAAP Diluted Earnings per Share of $0.48 1 Full Ye...

Halozyme to Report Fourth Quarter and Full Year 2022 Financial and Operating Results PR Newswire SAN DIEGO , Feb. 7, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2022...

Halozyme Appoints Barbara Duncan to its Board of Directors PR Newswire SAN DIEGO , Feb. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the appointment of Barbara Duncan to its Board of Directors. Ms. Duncan bri...

Summary Avid Bioservices is primed to more than double capacity over the next few quarters. Perception should change as Avid fills its new capacity and develops into a free cash flow machine. It would not surprise me to see fast growing, recession resistant cash flows valued at 20x,...

Summary Laughing Water Capital is a concentrated, long-biased investment partnership open to accredited investors. For the fourth quarter of 2022, an investment in Class A shares of Laughing Water Capital, net of all fees and expenses,  returned approximately 4.0% vs 7.6% and 6.2% ...

HALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024 PR Newswire SAN DIEGO , Jan. 11, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it has elected to redeem on March...

Halozyme Therapeutics ( NASDAQ: HALO ) on Tuesday said it expected 2023 total revenue of $815M to $845M, significantly below the consensus revenue estimate of $892.43M. Shares of the San Diego, Calif.-based company fell 7.3% to $51.61 after hours. HALO said it expects 2023...

Halozyme Provides 2023 Financial Guidance and Outlook PR Newswire 2023 Total Revenue Guidance of $815 to $845 Million Representing >20% Growth Over Expected 2022 Revenue 2023 Recurring Revenues from Royalties Projected to Grow by >20% to $445 to $...

Summary The stock of Halozyme Therapeutics, Inc. has moved up nicely in recent months, buoyed by solid third quarter results and positive commentary from the analyst firm community. However, Halozyme stock is hitting up against some price targets and insiders have notably started to sel...